Breaking Down Actinium Pharmaceuticals, Inc. (ATNM) Financial Health: Key Insights for Investors

Are you keeping a close watch on Actinium Pharmaceuticals, Inc. (ATNM) and wondering about their financial stability? For the year ended December 31, 2024, Actinium reported no revenue from product sales. Research and development expenses were $30.0 million, a decrease from $38.7 million in the prior year. The company's cash and cash equivalents totaled $72.9 million as of December 31, 2024, with the company anticipating that its existing resources will be sufficient to fund operations for more than 12 months. Let’s delve into the key financial insights that can help you assess the company's health and future prospects.

Actinium Pharmaceuticals, Inc. (ATNM) Revenue Analysis

Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company and as such, it currently does not have consistent revenue streams typical of commercial-stage companies. The company focuses on developing targeted radiotherapies to treat patients with cancers. Given its clinical stage, Actinium's financial health is primarily evaluated based on its ability to raise capital, manage expenses, and advance its clinical programs rather than on traditional revenue generation.

As a clinical-stage biopharmaceutical company, Actinium Pharmaceuticals primarily relies on funding through the issuance of common stock, preferred stock, warrants, and debt. These financial activities are crucial for sustaining operations and advancing clinical trials, as detailed in their financial reports.

Since Actinium Pharmaceuticals is in the clinical stage, it does not generate revenue from product sales. Instead, its financial performance is closely tied to its ability to manage expenses related to research and development (R&D) and general and administrative (G&A) activities. Investors should monitor these expenditures to assess the company's operational efficiency and financial discipline.

Here's a breakdown of what investors and stakeholders should consider regarding Actinium Pharmaceuticals' financial status:

• Reliance on Capital Markets: Actinium depends heavily on raising capital through equity and debt offerings to fund its operations.
• R&D Expenditure: A significant portion of the company’s funds is allocated to research and development activities, reflecting its focus on advancing clinical programs.
• Cash Burn Rate: Monitoring the cash burn rate is crucial to assess how quickly the company is using its available cash reserves.
• Clinical Trial Progress: The success and progression of clinical trials are pivotal. Positive results can significantly enhance the company's valuation and attract further investment.

Given the absence of traditional revenue streams, potential investors should focus on Actinium's ability to secure funding, manage its cash flow, and achieve clinical milestones. These factors are key indicators of the company's long-term viability and potential for future success.

For further insights into Actinium Pharmaceuticals, Inc. (ATNM) financial health, you can read more here: Breaking Down Actinium Pharmaceuticals, Inc. (ATNM) Financial Health: Key Insights for Investors

Actinium Pharmaceuticals, Inc. (ATNM) Profitability Metrics

Analyzing Actinium Pharmaceuticals, Inc. (ATNM)'s profitability involves examining several key metrics that provide insights into the company's financial health. These include gross profit, operating profit, and net profit margins, as well as trends in these metrics over time. Comparing these ratios with industry averages and analyzing operational efficiency, such as cost management and gross margin trends, are crucial for investors.

Actinium Pharmaceuticals is a clinical stage biopharmaceutical company and as such, it is typical to not have significant revenue or profits, especially when heavily investing in research and development. Therefore, traditional profitability metrics may not be the most relevant indicators of the company's potential.

Here's what we can glean from Actinium Pharmaceuticals, Inc.'s financial data:

• Gross Profit: As a clinical-stage biopharmaceutical company, Actinium often reports minimal or no revenue from product sales, especially if they are pre-commercialization. Therefore, gross profit figures might be negligible and not the primary focus of analysis.
• Operating Profit: Actinium's operating profit is significantly influenced by its investments in research and development (R&D) and general and administrative (G&A) expenses. A consistent operating loss is expected for such companies as they invest heavily in drug development. For example, in the 2023 fiscal year, Actinium reported an operating loss of $61.7 million.
• Net Profit Margins: Due to the substantial R&D and operating expenses, Actinium typically reports net losses. The net loss for the year ended December 31, 2023, was approximately $61.8 million.

The company's financial statements reveal these details:

• For the year ended December 31, 2023, Actinium Pharmaceuticals reported a net loss of approximately $61.8 million, or $1.41 per share.
• Research and development expenses totaled $33.9 million for the year ended December 31, 2023, compared to $29.9 million for the year ended December 31, 2022.
• General and administrative expenses were $27.9 million for the year ended December 31, 2023, compared to $24.7 million for the year ended December 31, 2022.

Trends in profitability over time are crucial. While Actinium is not yet profitable, monitoring the changes in net losses, R&D spending, and G&A expenses can provide insights into the company's operational efficiency and financial management. It's essential to consider whether increased spending is effectively driving the development of their drug candidates.

Given that Actinium is a development-stage company, traditional profitability ratios might not be the most useful. Instead, investors should focus on:

• Cash Burn Rate: How quickly the company is using its cash reserves to fund operations.
• Runway: How long the company can sustain its operations with its current cash reserves.
• Clinical Trial Progress: Milestones achieved in the development of their drug candidates.
• Partnerships and Funding: Any collaborations or financing deals that can extend the company's runway.

Operational efficiency for Actinium involves managing R&D costs effectively and controlling G&A expenses. Key indicators include:

• R&D Efficiency: Assessing the output from R&D spending in terms of clinical trial progress and potential drug approvals.
• G&A Expense Control: Keeping administrative costs in check to maximize resources available for drug development.

For detailed insights, you can explore further at: Breaking Down Actinium Pharmaceuticals, Inc. (ATNM) Financial Health: Key Insights for Investors

Actinium Pharmaceuticals, Inc. (ATNM) Debt vs. Equity Structure

Understanding Actinium Pharmaceuticals, Inc. (ATNM)'s approach to financing its operations and growth is crucial for investors. This involves analyzing the company's debt levels, debt-to-equity ratio, and how it strategically uses both debt and equity.

As of the fiscal year 2024, Actinium Pharmaceuticals, Inc. (ATNM) has a mix of short-term and long-term debt obligations. Short-term debt includes obligations due within a year, while long-term debt extends beyond a year. Keeping tabs on these figures helps in assessing the company’s immediate and future financial commitments.

The debt-to-equity ratio is a key metric to evaluate Actinium Pharmaceuticals, Inc. (ATNM)'s financial leverage. It compares the total debt to the total equity, providing insights into how much the company relies on debt versus equity to finance its assets. A high ratio indicates greater financial risk, while a lower ratio suggests a more conservative approach. The company's debt-to-equity ratio can be compared against industry standards to see how it measures up against its peers.

Recent activities, such as new debt issuances, changes in credit ratings, or refinancing efforts, provide insight into Actinium Pharmaceuticals, Inc. (ATNM)'s financial strategies. These actions can impact the company’s financial flexibility and cost of capital. Monitoring these events helps investors understand how Actinium Pharmaceuticals, Inc. (ATNM) manages its debt.

Actinium Pharmaceuticals, Inc. (ATNM) strategically balances debt and equity to fund its operations and growth initiatives. Here's an overview:

• Debt Financing:
  • Allows Actinium Pharmaceuticals, Inc. (ATNM) to maintain equity control.
  • Interest payments on debt are tax-deductible, providing a financial advantage.
  • Requires careful management to avoid over-leveraging.
• Equity Funding:
  • Does not require repayment, reducing financial strain.
  • Can dilute existing shareholders' ownership.
  • Provides a cushion during financial downturns.

The following table illustrates a hypothetical comparison of debt and equity financing for Actinium Pharmaceuticals, Inc. (ATNM):

Understanding Actinium Pharmaceuticals, Inc. (ATNM)'s debt and equity structure provides investors with a clearer picture of its financial health and strategic direction. For more insights into Actinium Pharmaceuticals, Inc. (ATNM), check out: Exploring Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile: Who’s Buying and Why?

Actinium Pharmaceuticals, Inc. (ATNM) Liquidity and Solvency

Assessing Actinium Pharmaceuticals, Inc.'s financial health requires a close look at its liquidity and solvency. Liquidity refers to the company's ability to meet its short-term obligations, while solvency concerns its ability to meet long-term obligations. Key metrics and trends in cash flow provide insights into the company's financial stability.

Here's an overview of Actinium Pharmaceuticals, Inc.’s liquidity position:

• Current and Quick Ratios: These ratios measure a company's ability to pay off its current liabilities with its current assets. A higher ratio generally indicates better liquidity.
• Working Capital Trends: Monitoring the trend of working capital (current assets minus current liabilities) can reveal whether the company's short-term financial health is improving or deteriorating.

An overview of Actinium Pharmaceuticals, Inc.’s cash flow statements is crucial for understanding its financial activities:

• Operating Cash Flow: This indicates the cash generated from the company's core business operations. A positive and increasing operating cash flow is generally a healthy sign.
• Investing Cash Flow: This section reflects cash spent on investments, such as property, plant, and equipment (PP&E). Consistent investments can indicate growth initiatives.
• Financing Cash Flow: This includes activities related to debt, equity, and dividends. It shows how the company raises capital and returns it to investors.

To provide a clearer picture, here's a hypothetical snapshot of Actinium Pharmaceuticals, Inc.'s key financial data based on the 2024 fiscal year:

Actinium Pharmaceuticals, Inc., like many biotech companies, may face liquidity challenges due to high research and development costs and the long timelines associated with drug development. Investors should monitor these trends closely to assess the company's ability to fund its operations and achieve its strategic goals. Analyzing these elements helps stakeholders understand the company's financial strengths and potential vulnerabilities.

To gain more insight into the values that drive Actinium Pharmaceuticals, Inc., explore Mission Statement, Vision, & Core Values of Actinium Pharmaceuticals, Inc. (ATNM).

Actinium Pharmaceuticals, Inc. (ATNM) Valuation Analysis

Determining whether Actinium Pharmaceuticals, Inc. (ATNM) is overvalued or undervalued requires a multifaceted approach, incorporating various financial ratios, stock performance analysis, and analyst opinions. Key metrics such as price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) are essential for assessing its current market valuation.

As of April 20, 2025, up-to-date financial ratios for Actinium Pharmaceuticals, Inc. (ATNM) are essential to accurately assess its valuation. Since real-time data fluctuates, consulting financial analysis platforms for the most current figures is crucial. Here's how these ratios generally factor into valuation:

• Price-to-Earnings (P/E) Ratio: This ratio compares the company's stock price to its earnings per share (EPS). A higher P/E ratio might suggest that the stock is overvalued, or that investors expect high growth in the future. Conversely, a lower P/E ratio could indicate undervaluation, or reflect lower expected growth.
• Price-to-Book (P/B) Ratio: The P/B ratio compares a company's market capitalization to its book value of equity. A lower P/B ratio may suggest undervaluation, as the stock price is low relative to the company's net asset value. However, it could also indicate underlying problems with the company's financials.
• Enterprise Value-to-EBITDA (EV/EBITDA): This ratio compares a company's enterprise value (total market value plus debt, minus cash) to its earnings before interest, taxes, depreciation, and amortization (EBITDA). It's often used as a valuation tool because it provides a more comprehensive view of a company's financial performance than the P/E ratio. A lower EV/EBITDA multiple might suggest undervaluation.

Analyzing Actinium Pharmaceuticals, Inc. (ATNM)'s stock price trends over the last 12 months (or longer) provides insights into market sentiment and investor confidence. Significant price appreciation could indicate positive market perception, while a declining stock price might suggest concerns about the company's prospects.

Actinium Pharmaceuticals, Inc. (ATNM) does not currently offer a dividend yield, as it is a development-stage company focused on clinical trials and research, rather than distributing profits to shareholders.

Analyst consensus on Actinium Pharmaceuticals, Inc. (ATNM)'s stock valuation typically includes ratings such as 'buy,' 'hold,' or 'sell.' These ratings represent the overall sentiment of financial analysts regarding the stock's potential. To determine the current analyst consensus, it is important to consult recent analyst reports from reputable financial analysis platforms.

For a deeper dive into the investors and their rationale behind investing in Actinium Pharmaceuticals, Inc. (ATNM), check out: Exploring Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile: Who’s Buying and Why?

Actinium Pharmaceuticals, Inc. (ATNM) Risk Factors

Actinium Pharmaceuticals, Inc. (ATNM) faces a variety of risks that could significantly impact its financial health. These risks span from internal operational challenges to external market and regulatory pressures. Understanding these factors is crucial for investors assessing the company’s viability and potential for growth.

Here's an overview of the key risks:

• Industry Competition: The biotechnology industry is intensely competitive. Actinium faces competition from other companies, including those with greater financial, technical, marketing, and human resources. These competitors may develop products and therapies that are more effective or less expensive than Actinium's, potentially capturing market share and limiting the company's revenue.
• Regulatory Changes: The development, manufacturing, and marketing of Actinium's products are subject to extensive regulation by government authorities in the United States and other countries. Changes in regulatory policies or requirements could increase the costs and time required to bring new products to market, delay or prevent regulatory approval of Actinium's products, or impose restrictions on the marketing and sale of approved products.
• Market Conditions: Unfavorable market conditions, such as economic recessions or downturns in the biotechnology industry, could negatively impact Actinium's ability to raise capital, commercialize its products, and achieve profitability. Market volatility and investor sentiment can also affect the company's stock price, making it more difficult to raise funds through equity offerings.

Operational, financial, and strategic risks are often detailed in Actinium's earnings reports and filings with the Securities and Exchange Commission (SEC). These documents provide insights into the specific challenges the company faces and how management is addressing them.

Some key operational risks include:

• Clinical Trial Delays or Failures: The success of Actinium's product pipeline depends on the successful completion of clinical trials. Delays in clinical trial enrollment, unexpected adverse events, or failure to meet endpoints could significantly delay or prevent the approval of Actinium's products.
• Manufacturing Challenges: Manufacturing issues, such as supply chain disruptions, quality control problems, or capacity constraints, could disrupt the production and supply of Actinium's products. These issues could lead to product shortages, increased costs, and reputational damage.
• Reliance on Key Personnel: Actinium's success depends on the contributions of its key management and scientific personnel. The loss of one or more of these individuals could disrupt the company's operations and delay the development of its products.

Financial risks that Actinium faces include:

• Need for Additional Funding: Actinium requires significant capital to fund its research and development activities, clinical trials, and commercialization efforts. The company may need to raise additional funds through equity offerings, debt financing, or other sources. However, there is no guarantee that such funding will be available on favorable terms, or at all.
• Limited Revenue: Actinium currently generates limited revenue from product sales. The company's ability to achieve profitability depends on the successful development and commercialization of its product pipeline. However, there is no guarantee that Actinium will be able to generate sufficient revenue to cover its expenses and achieve profitability.
• High Operating Expenses: Actinium incurs significant operating expenses related to research and development, clinical trials, and general and administrative activities. These expenses could increase as the company advances its product pipeline and expands its operations.

Strategic risks for Actinium include:

• Competition: Actinium faces intense competition from other biotechnology companies that are developing similar products. Competitors may have greater financial resources, more advanced technologies, or more experience in clinical development and regulatory affairs.
• Intellectual Property Protection: Actinium's success depends on its ability to protect its intellectual property. The company may face challenges in obtaining and maintaining patent protection for its products and technologies. In addition, third parties may assert that Actinium's products infringe their intellectual property rights.
• Market Acceptance: Even if Actinium's products are approved by regulatory authorities, there is no guarantee that they will be accepted by physicians, patients, or payers. Factors such as cost, efficacy, safety, and convenience could affect the market acceptance of Actinium's products.

Mitigation strategies or plans, if available, are typically outlined in the company's SEC filings or investor presentations. These strategies may include diversifying the product pipeline, securing strategic partnerships, implementing cost-cutting measures, or strengthening intellectual property protection.

For further insights into Actinium Pharmaceuticals, Inc. (ATNM), consider exploring this resource: Exploring Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile: Who’s Buying and Why?

Actinium Pharmaceuticals, Inc. (ATNM) Growth Opportunities

Actinium Pharmaceuticals, Inc. (ATNM) is focused on the development of targeted radiotherapies for advanced cancers. Future growth prospects for Actinium Pharmaceuticals, Inc. (ATNM) hinge on several key factors, including product innovation, strategic partnerships, and competitive advantages.

Key growth drivers for Actinium Pharmaceuticals, Inc. (ATNM) include:

• Product Innovations: Development and clinical advancement of novel targeted radiotherapies.
• Market Expansion: Successfully navigating regulatory pathways to commercialize products in key markets.
• Strategic Collaborations: Forming partnerships to expand research and development capabilities and market reach.

While specific future revenue growth projections and earnings estimates for Actinium Pharmaceuticals, Inc. (ATNM) are subject to market conditions and clinical trial outcomes, several strategic initiatives could significantly influence its trajectory:

• Clinical Trial Success: Positive results from ongoing and planned clinical trials for Actimab-A and Iomab-B, particularly in pivotal studies, are critical for regulatory approvals and subsequent commercial success.
• Regulatory Approvals: Securing FDA and other regulatory approvals for its lead product candidates.
• Commercialization Strategies: Effective strategies for manufacturing, marketing, and distribution of approved products.

Actinium Pharmaceuticals, Inc. (ATNM) operates in a competitive landscape with other biotechnology and pharmaceutical companies developing cancer therapies. Its competitive advantages include:

• Targeted Radiotherapy Platform: Actinium's expertise in developing targeted radiotherapies provides a unique approach to cancer treatment, potentially offering advantages in terms of efficacy and reduced toxicity compared to traditional therapies.
• Proprietary Technology: Owning intellectual property related to its drug candidates and delivery systems.

More insights about Actinium Pharmaceuticals, Inc. (ATNM) can be found here: Mission Statement, Vision, & Core Values of Actinium Pharmaceuticals, Inc. (ATNM).